FIELD: biotechnology.
SUBSTANCE: presented is an improved Fab-fragment of an antibody to human NGF, as well as disclosed are compositions and methods of treating postoperative pain by such an antibody fragment.
EFFECT: said Fab-fragment retains high neutralizing activity and reduces system side effects, arising from systemic exposure, with simultaneous manifestation of local drug exposure.
8 cl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC PROTEIN COMPOSED OF AN NGF ANTAGONIST DOMAIN AND A TNFΑ ANTAGONIST DOMAIN | 2015 |
|
RU2788122C2 |
| NGF ANTIBODIES AND RELATED METHODS | 2019 |
|
RU2838175C2 |
| ANTIBODIES BINDING TO GPRC5D | 2020 |
|
RU2841523C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| ANTIBODY AND DRUG CONJUGATES FOR DESTRUCTION OF HEMATOPOIETIC STEM CELLS | 2017 |
|
RU2781444C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| EphA4 ANTIBODY | 2016 |
|
RU2719158C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| ANTIBODIES THAT BIND TO CANCER CELLS AND PROVIDE TARGETED TRANSFER OF RADIONUCLIDES TO SAID CELLS | 2020 |
|
RU2833191C2 |
